Literature DB >> 8468441

The costs of depression.

P Kind1, J Sorensen.   

Abstract

Depression is one of the commonest conditions seen by general practitioners. Conventional treatments are typically drug based, and usually involve one of the tricyclic preparations. The evaluation of new treatments requires an understanding of the costs and benefits of existing alternatives, to provide a comparative framework for general practitioners and others concerned with the treatment and management of depressed patients. This paper presents estimates of the direct costs associated with the treatment of patients in England and Wales. These amount to some 420 million pounds annually. Pharmaceutical costs represent a relatively small proportion of this total. Substantial indirect costs are generated through lost productivity, and these may exceed 3 billion pounds.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8468441     DOI: 10.1097/00004850-199300730-00010

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  33 in total

1.  The quantity and quality of clinical practice guidelines for the management of depression in primary care in the UK.

Authors:  P Littlejohns; F Cluzeau; R Bale; J Grimshaw; G Feder; S Moran
Journal:  Br J Gen Pract       Date:  1999-03       Impact factor: 5.386

2.  The added costs of depression to medical care.

Authors:  K Franco; M Tamburino; N Campbell; J Zrull; C Evans; D Bronson
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

Review 3.  Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 1: Depression and its treatment.

Authors:  J A Henry; C A Rivas
Journal:  Pharmacoeconomics       Date:  1997-05       Impact factor: 4.981

Review 4.  Selective serotonin reuptake inhibitors. Assessment for formulary inclusion.

Authors:  B H Guze
Journal:  Pharmacoeconomics       Date:  1996-05       Impact factor: 4.981

Review 5.  Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 2: Cost-effectiveness analyses.

Authors:  J A Henry; C A Rivas
Journal:  Pharmacoeconomics       Date:  1997-06       Impact factor: 4.981

6.  Which antidepressant? A commentary from general practice on evidence-based medicine and health economics.

Authors:  D P Kernick
Journal:  Br J Gen Pract       Date:  1997-02       Impact factor: 5.386

Review 7.  Paroxetine. A pharmacoeconomic evaluation of its use in depression.

Authors:  M I Wilde; R Whittington
Journal:  Pharmacoeconomics       Date:  1995-07       Impact factor: 4.981

Review 8.  Measuring quality of life in patients with depression or anxiety.

Authors:  D Whalley; S P McKenna
Journal:  Pharmacoeconomics       Date:  1995-10       Impact factor: 4.981

Review 9.  Escitalopram: a pharmacoeconomic review of its use in depression.

Authors:  Katherine F Croom; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 10.  Identifying the needs of penile cancer sufferers: a systematic review of the quality of life, psychosexual and psychosocial literature in penile cancer.

Authors:  Satish B Maddineni; Maurice M Lau; Vijay K Sangar
Journal:  BMC Urol       Date:  2009-08-08       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.